ACADIA Pharmaceuticals (ACAD) Receives Price Target

ACADIA Pharmaceuticals (ACAD) : 6 investment research analysts covering ACADIA Pharmaceuticals (ACAD) have an average price target of $45.83 for the near short term. The highest target price given by the Brokerage Firm to the stock is $60 and the lowest target is $39 for the short term. Analysts expect the variance to be within $7.73 of the average price.

ACADIA Pharmaceuticals (ACAD) : 6 analysts are covering ACADIA Pharmaceuticals (ACAD) and their average rating on the stock is 1.67, which is read as a Buy. 4 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 2 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.


Also, Brokerage firm Bank of America downgrades its rating on ACADIA Pharmaceuticals (NASDAQ:ACAD). The shares have been rated Neutral. Previously, the analysts had a Buy rating on the shares. The rating by the firm was issued on June 22, 2016.

ACADIA Pharmaceuticals (NASDAQ:ACAD): The stock opened at $32.19 on Thursday but the bulls could not build on the opening and the stock topped out at $32.69 for the day. The stock traded down to $31.53 during the day, due to lack of any buying support eventually closed down at $32.10 with a loss of -0.09% for the day. The stock had closed at $32.13 on the previous day. The total traded volume was 1,367,940 shares.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Companys drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinsons disease psychosis, Alzheimers disease psychosis, Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin, is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan, has discovered and engaged in the development of small-molecule product candidates, such as alpha adrenergic agonists and muscarinic receptors.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.